CRNX - クリネティック・ファ―マシュ―ティカルズ (Crinetics Pharmaceuticals Inc.)

CRNXのニュース

   Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel - BioSpace  2021/06/22 10:55:43 BioSpace
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel BioSpace
   Crinetics Pharmaceuticals synthesizes new melanocortin MC2 receptor antagonists  2021/06/03 13:58:13 BioWorld
   Leerink Partners Maintains Their Buy Rating on Crinetics Pharmaceuticals (CRNX)  2021/05/31 07:58:58 Smarter Analyst
In a report issued on May 27, Joseph Schwartz from Leerink Partners maintained a Buy rating on Crinetics Pharmaceuticals (CRNX), with a price The post Leerink Partners Maintains Their Buy Rating on Crinetics Pharmaceuticals (CRNX) appeared first on Smarter Analyst .
   Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from H.C. Wainwright  2021/05/11 10:27:02 Smarter Analyst
H.C. The post Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst .
   Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight  2021/05/27 00:00:00 Benzinga
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight Levoketoconazole is expected to emerge as a potential therapy owing to its novelty and oral RoA, thus expected to gain maximum Cushing's Syndrome patient pool. DelveInsight's ' Cushing's Syndrome Pipeline Insights ' report offers a detailed picture of the emerging therapies expected to enter the Cushing's Syndrome market along with detailed coverage of the pipeline therapies under development in pre-clinical as well as clinical stages of development, partnerships taking place in the domain, recent happenings in space and growth prospects across the Cushing's Syndrome domain. Some of the key highlights of the Cushing's Syndrome Pipeline report: Cushing's Syndrome Pipeline report offers a comprehensive analysis of 10+ key players and 10+ key therapies. Cushing's Syndrome pipeline comprises Relacorilant (Corcept Therapeutics), Levoketoconazole (Strongbridge Biopharma), CRN-04894 (Crinetics Pharmaceuticals), and several others expected to get launched in the next decade.
   Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update  2020/11/06 13:31:00 GlobeNewswire
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received…
   BidaskClub Downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Strong Sell  2020/10/25 06:52:41 Zolmax News
Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday, BidAskClub reports. CRNX has been the topic of a number of other reports. Zacks Investment Research cut shares of Crinetics Pharmaceuticals from a “buy” rating to a […]
   Crinetics Pharmaceuticals (NASDAQ:CRNX) Downgraded by BidaskClub to Strong Sell  2020/10/24 08:52:44 Stock Observer
BidaskClub cut shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a sell rating to a strong sell rating in a report published on Friday, BidAskClub reports. A number of other research firms have also weighed in on CRNX. Zacks Investment Research lowered shares of Crinetics Pharmaceuticals from a buy rating to a hold rating in a research […]
   Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now?  2020/05/14 12:51:00 Zacks Investment Research
Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should Know  2020/04/17 16:00:07 Zacks Investment Research
Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

calendar